ARTRYA

Coronary Artery Disease. We see you.

ASX ANNOUNCEMENT

20 July 2022

QUARTERLY RESULTS CONFERENCE CALL

Artificial intelligence medical technology company Artrya Limited (ASX: AYA, Artrya or the Company) will be releasing its June 2022 quarterly report to the ASX on Tuesday, 26 July 2022.

The Company advises it will be holding an investor and analyst conference call discussing the June 2022 quarter results at 1pm AEST (11am AWST) on Tuesday, 26 July 2022.

Join the conference call on Zoom by clicking here.

This announcement was approved by the Company's Managing Director, John Barrington, on behalf of the Artrya Board.

For further information please contact

Investor Enquiries: Media Enquiries: John Barrington Felicity Heath Artrya Limited Daymark 0419 850 502 0457 196 603

investors@artrya.com felicity.heath@daymark.com.au

About Artrya

Based in Perth, Western Australia, Artrya was founded in 2018 and commenced operations in early 2019. Artrya Ltd is listed on the Australian Securities Exchange (ASX: AYA).

Artrya is an applied artificial intelligence healthcare company that works alongside clinicians to improve the diagnosis of coronary heart disease and develop a holistic overview of a patient at risk. The Company has developed deep learning algorithms that will allow for the prediction and prevention of acute coronary events.

For more information, see www.artrya.com